NCT00034749View on ClinicalTrials.gov

The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

March 31, 2006

Conditions
Schizophrenia
Interventions
DRUG

Risperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00034749 - The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia | Biotech Hunter | Biotech Hunter